Expert Consensus on Effective Management of Chemotherapy-Induced Nausea and Vomiting: An Indian Perspective.
CINV
antiemetics
consensus
quality of life
risk scoring
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
30
09
2019
accepted:
05
03
2020
entrez:
16
4
2020
pubmed:
16
4
2020
medline:
16
4
2020
Statut:
epublish
Résumé
Chemotherapy-induced nausea and vomiting (CINV) is one of the most common and feared side effects in cancer patients undergoing chemotherapy. Scientific evidence proves its detrimental impact on a patient's quality of life (QoL), treatment compliance, and overall healthcare cost. Despite the CINV-management landscape witnessing a radical shift with the introduction of novel, receptor-targeting antiemetic agents, this side effect remains a chink in the armor of a treating oncologist. Though global guidelines acknowledge patient-specific risk factors and chemotherapeutic agent emetogenic potential in CINV control, a "one-fit-for-all" approach cannot be followed across all geographies. Hence, in a pioneering attempt, India-based oncologists conveyed easily implementable, region-specific, consensus-based statements on CINV prevention and management. These statements resulted from integrating the analysis of scientific evidence and guidelines on CINV by the experts, with their clinical experience. The statements will strengthen decision-making abilities of Indian oncologists/clinicians and help in achieving consistency in CINV prevention and management in the country. Furthermore, this document shall lay the foundation for developing robust Indian guidelines for CINV prevention and control.
Identifiants
pubmed: 32292721
doi: 10.3389/fonc.2020.00400
pmc: PMC7120415
doi:
Types de publication
Journal Article
Langues
eng
Pagination
400Informations de copyright
Copyright © 2020 Vaid, Gupta, Doval, Agarwal, Nag, Patil, Goswami, Ostwal, Bhagat, Patil and Barkate.
Références
Support Care Cancer. 2013 Jun;21(6):1561-8
pubmed: 23274926
CMAJ. 1993 Aug 1;149(3):296-302
pubmed: 8339175
Ann Oncol. 2012 Aug;23(8):1986-92
pubmed: 22396444
Int J Clin Oncol. 2015 Oct;20(5):855-65
pubmed: 25681876
Support Care Cancer. 2011 Oct;19(10):1549-63
pubmed: 20811914
Indian J Cancer. 2013 Oct-Dec;50(4):285-91
pubmed: 24369195
Support Care Cancer. 2019 Mar;27(3):1139-1147
pubmed: 30094732
Expert Opin Drug Saf. 2014 Oct;13(10):1407-22
pubmed: 25196083
Drugs Context. 2015 Jul 28;4:212285
pubmed: 26322114
Support Care Cancer. 2011 Jun;19(6):807-13
pubmed: 20461438
Support Care Cancer. 2018 Feb;26(2):557-564
pubmed: 28871358
Am J Clin Oncol. 1991 Jun;14(3):238-42
pubmed: 2031511
Cancer Res Treat. 2016 Oct;48(4):1420-1428
pubmed: 26875197
Support Care Cancer. 2007 Nov;15(11):1293-1300
pubmed: 17436025
J Pain Symptom Manage. 2001 Feb;21(2):113-20
pubmed: 11226762
Oncologist. 2018 May;23(5):603-616
pubmed: 29330211
J Manag Care Pharm. 2012 Jun;18(5):385-94
pubmed: 22663171
Lancet Oncol. 2009 Feb;10(2):115-24
pubmed: 19135415
Med Oncol. 2017 Dec 16;35(1):12
pubmed: 29248965
Support Care Cancer. 2011 Mar;19 Suppl 1:S1-4
pubmed: 20505956
Cancer Manag Res. 2018 Oct 04;10:4249-4255
pubmed: 30323680
Chemother Res Pract. 2016;2016:3439707
pubmed: 26925265
J Pain Symptom Manage. 2016 Jun;51(6):987-93
pubmed: 26891606
Expert Opin Pharmacother. 2013 Apr;14(6):757-66
pubmed: 23496347
Support Care Cancer. 2014 Jun;22(6):1685-97
pubmed: 24590374
J Clin Diagn Res. 2017 May;11(5):FC10-FC14
pubmed: 28658796
Ann Oncol. 2006 Sep;17(9):1441-9
pubmed: 16766588
Support Care Cancer. 2016 Nov;24(11):4617-25
pubmed: 27334131
J Clin Oncol. 2014 Jan 10;32(2):101-6
pubmed: 24323030
J Pain Symptom Manage. 2007 Sep;34(3):265-76
pubmed: 17604591
Asian Pac J Cancer Prev. 2016;17(4):1661-75
pubmed: 27221836
Cancer Pract. 1999 Mar-Apr;7(2):59-65
pubmed: 10352062
Support Care Cancer. 2017 Jan;25(1):145-154
pubmed: 27591991
Psychosom Med. 2016 Oct;78(8):959-965
pubmed: 27428859
Cancer. 1989 Sep 1;64(5):1117-22
pubmed: 2667749
Support Care Cancer. 2018 Jan;26(1):21-32
pubmed: 28861627
Ann Palliat Med. 2018 Apr;7(2):221-233
pubmed: 29764184
J Community Support Oncol. 2015 Jun;13(6):209-13
pubmed: 26270519
Drugs. 2009;69(13):1853-78
pubmed: 19719336
Biomed Res Int. 2015;2015:943618
pubmed: 26425563
Ann Oncol. 1996 Feb;7(2):189-95
pubmed: 8777177
Oncologist. 2004;9(1):80-9
pubmed: 14755017
Singapore Med J. 2010 Nov;51(11):871-5
pubmed: 21140114
Support Care Cancer. 2011 Jan;19(1):131-40
pubmed: 20101417
J Glob Oncol. 2016 Nov 9;3(4):346-359
pubmed: 28831443
Crit Rev Oncol Hematol. 2016 Mar;99:13-36
pubmed: 26697988
Indian J Pharmacol. 2017 Nov-Dec;49(6):451-457
pubmed: 29674800
Onco Targets Ther. 2018 Oct 04;11:6459-6478
pubmed: 30323622
Support Care Cancer. 2005 Apr;13(4):219-27
pubmed: 15538640
J Clin Oncol. 2015 Mar 10;33(8):910-5
pubmed: 25624439
Support Care Cancer. 2002 Mar;10(2):139-45
pubmed: 11862503
Eur J Cancer Clin Oncol. 1983 Feb;19(2):203-8
pubmed: 6681766
Cancer. 2004 May 15;100(10):2261-8
pubmed: 15139073
Ecancermedicalscience. 2015 Aug 25;9:567
pubmed: 26435740
Pediatr Blood Cancer. 2019 Mar;66(3):e27551
pubmed: 30426714
J Support Oncol. 2010 Mar-Apr;8(2 Suppl 1):5-9
pubmed: 20629452
Cancer. 2003 Dec 1;98(11):2473-82
pubmed: 14635083
BMC Med. 2015 Jun 18;13:142
pubmed: 26084332
Support Care Cancer. 2004 Jan;12(1):58-63
pubmed: 14655041
Support Care Cancer. 1998 May;6(3):244-7
pubmed: 9629877
Support Care Cancer. 2005 Oct;13(10):812-8
pubmed: 15834590
Drugs. 1998 Feb;55(2):173-89
pubmed: 9506240
Asian Pac J Cancer Prev. 2010;11(6):1523-7
pubmed: 21338191
Ann Oncol. 2007 Feb;18(2):233-40
pubmed: 17108149
Cancer Sci. 2013 Jun;104(6):711-7
pubmed: 23480814
Int J Gynecol Cancer. 2012 Jan;22(1):139-45
pubmed: 22080888
Chest. 2006 Jan;129(1):174-81
pubmed: 16424429
N Engl J Med. 1983 Sep 29;309(13):796
pubmed: 6684209
Expert Opin Pharmacother. 2003 Dec;4(12):2297-303
pubmed: 14640928
South Asian J Cancer. 2015 Jan-Mar;4(1):7-10
pubmed: 25839011